By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gamida Cell Ltd. 

Harey Yehuda 54
P.O.B. 94
Savyon    56530  Israel
Phone: 03-534-7482 Fax: 03-534-3067



Company News
Novartis AG (NVS)-Backed Gamida Cell Nabs Breakthrough Tag for NiCord 10/11/2016 6:16:06 AM
Gamida Cell Announces Appointment Of Julian Adams, Ph.D. And Kenneth I. Moch To Its Board Of Directors 9/15/2016 10:26:51 AM
Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source 7/27/2016 8:26:15 AM
ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016 6/6/2016 9:36:04 AM
Gamida Cell Announces $4.4 Million Grant From The Israeli Government 5/23/2016 8:38:33 AM
Gamida Cell Presents Additional Positive Data Of NiCord In Blood Cancer Patients At EBMT 2016 4/5/2016 10:32:15 AM
Gamida Cell Reports Positive Top Line Results Of International, Multi-Center, Phase I/II Study Of Nicord For Blood Cancers, Demonstrating Rapid And Durable Hematopoietic Recovery 12/7/2015 12:57:40 PM
Elbit Imaging Ltd. (EMITF) Announces Its Indirect Associate, Gamida Cell, Has Entered Into Agreement With Novartis Pharma AG (NVS) 10/12/2015 10:12:56 AM
Novartis AG (NVS) Takes Another 2.5% Stake in Gamida Cell 10/12/2015 6:48:33 AM
Gamida Cell Achieves Major Regulatory Milestone: FDA And European Medicines Agency Respond Positively to NiCord Phase III Study Design Outline 8/10/2015 6:13:08 AM